Thyroid Eye Symptoms: Labs, Diagnosis, and Next Steps for Women

What Are Thyroid Eye Symptoms and Why Do They Happen?

Thyroid eye symptoms arise when the immune system attacks tissue behind and around the eyeball. The result is swelling of the eye muscles and fatty tissue inside the orbit, pushing the eye forward (proptosis) and causing a range of symptoms from mild dryness to serious vision changes.

The underlying driver in the large majority of cases is Graves disease, an autoimmune condition in which antibodies called thyroid-stimulating immunoglobulins (TSIs) or TSH receptor antibodies (TRAb) attach to receptors on both thyroid cells and orbital fibroblasts. This shared receptor target is why your eyes and thyroid are attacked together, even though they sit far apart in your body.

Orbital fibroblasts respond to TSI stimulation by producing excess glycosaminoglycans, particularly hyaluronic acid, which retains water and dramatically expands the orbital soft tissue volume. Research published in Thyroid estimates that orbital volume can increase by 20-30% in active TED. Because the bony orbit cannot expand, pressure builds outward (proptosis) and inward against the optic nerve.

The Six Common Symptoms You Might Notice

1. Proptosis (bulging or prominent eyes): The most recognizable sign. One eye may protrude more than the other, which is an important asymmetry to report.
2. Eyelid retraction: Upper or lower lids appear pulled back, giving a wide-eyed or staring appearance.
3. Dry eyes, gritty sensation, or tearing: Incomplete eyelid closure exposes the cornea.
4. Periorbital swelling and puffiness: Especially noticeable in the morning, often mistaken for allergies.
5. Double vision (diplopia): Caused by restricted or inflamed extraocular muscles. The inferior and medial rectus muscles are most commonly affected.
6. Pressure, ache, or pain behind the eyes: Particularly with eye movement.

Blurred vision or a change in color perception is a red-flag symptom requiring urgent same-day evaluation, as it may signal compressive optic neuropathy.

Why Women Are at Much Higher Risk

Graves disease affects women at a rate roughly five to ten times higher than men, which directly explains the female predominance in TED. This sex disparity connects to estrogen-driven immune modulation, with estrogen generally amplifying Th2-mediated humoral immunity, the pathway most relevant to autoantibody production in Graves disease.

Reproductive transitions (puberty, postpartum, perimenopause) each carry measurable fluctuations in thyroid autoimmunity. The two incidence peaks for Graves disease in women occur around ages 40-44 and again around 60-64, the second of which overlaps directly with the menopause transition.

Life-Stage Breakdown: How TED Differs Across Your Reproductive Journey

TED is not a single disease experience. Hormonal context changes how it presents, how severe it becomes, and how it should be managed.

Reproductive Years (Ages 20-45)

This is the highest-risk window. Stress, infection, or a new diagnosis of Graves disease can all trigger or unmask TED. Women in this age group are also the most likely to be planning pregnancy, making TRAb testing essential because elevated TRAb at or above three times the upper limit of normal in the third trimester predicts neonatal Graves hyperthyroidism.

Perimenopause

Estrogen decline during perimenopause can destabilize immune tolerance. Thyroid autoantibody titers, including TRAb, may fluctuate or surge during this window. Some women first develop Graves disease in their late 40s and present with TED symptoms they initially attribute to perimenopausal changes, particularly the fatigue, sleep disruption, and mood shifts that overlap. Lid retraction and proptosis in a perimenopausal woman with a new tremor, unexplained weight loss, or palpitations should prompt immediate thyroid workup rather than defaulting to a menopause-only explanation.

Postpartum

The postpartum period carries the highest immune rebound risk of any life stage. Postpartum thyroiditis affects approximately 5-9% of women, and for women with pre-existing Graves disease or elevated TRAb, TED can flare in the months after delivery. Breastfeeding does not protect against this. Any new or worsening eye symptoms in the 6-12 months after birth warrant prompt evaluation, not watchful waiting.

Post-Menopause

Older women with TED tend to have more fibrotic, less inflamed disease, which means the active inflammatory phase (where anti-inflammatory treatments work best) may have passed. They may still have significant proptosis and mechanical complications requiring surgical correction.

Which Labs Should You Get? A Specific Checklist

The diagnosis of TED rests on a combination of clinical examination, serology, and imaging. No single test is diagnostic on its own.

First-Line Blood Tests

• TSH (thyroid-stimulating hormone): The initial screening test. A suppressed TSH (typically <0.1 mU/L) in the context of eye symptoms strongly suggests hyperthyroidism from Graves disease, but TSH can be normal in euthyroid TED (roughly 5-10% of TED cases).
• Free T4 and Free T3: Confirm the degree of thyroid hormone excess. Free T3 disproportionate elevation points to T3 toxicosis, common in Graves disease.
• TSI (thyroid-stimulating immunoglobulin): The most specific antibody for Graves-related TED. The FDA-cleared Thyretain assay detects TSI with sensitivity above 95% in active Graves disease. A positive TSI result in a woman with bulging eyes is highly confirmatory.
• TRAb (thyrotropin receptor antibody): Covers both stimulating and blocking TRAb. TRAb levels correlate with TED activity and severity, and the European Thyroid Association recommends TRAb measurement at diagnosis and during follow-up in all patients with Graves hyperthyroidism.
• Anti-thyroid peroxidase (TPO) and anti-thyroglobulin antibodies: Less specific for TED, but elevated TPO antibodies support a diagnosis of autoimmune thyroid disease and may prompt closer monitoring.

When to Add These Tests

• Complete metabolic panel (CMP) and CBC: If systemic hyperthyroidism symptoms are present or if methimazole treatment is being considered (baseline liver function and WBC).
• Fasting glucose and HbA1c: Thyroid hormones affect insulin sensitivity. Women with PCOS and coincident thyroid disease are at elevated risk for metabolic dysregulation and deserve metabolic screening at the time of TED diagnosis.
• Bone density (DEXA scan): Chronic hyperthyroidism accelerates bone loss. Women who are postmenopausal or who have had prolonged untreated hyperthyroidism should have a baseline DEXA.

Imaging

Orbital MRI is preferred over CT when available because it avoids radiation and better characterizes active soft-tissue inflammation (high T2 signal in swollen muscles predicts response to anti-inflammatory treatment). CT is used when MRI is contraindicated or when bony decompression planning is needed.

The Clinical Activity Score (CAS) is a 7-point validated tool used at the bedside by ophthalmologists to grade active TED. A CAS of 3 or higher defines clinically active disease and is the threshold at which immunosuppressive therapy, including the biologic teprotumumab (Tepezza), is considered.

Understanding Your Results: What the Numbers Mean

| Test | Result That Points to TED | What to Do | |---|---|---| | TSH | <0.1 mU/L | Add Free T4, Free T3, TRAb, TSI | | TSI | Positive (above assay cutoff) | Refer to endocrinology and ophthalmology | | TRAb | >2x upper limit of normal | Same-day referral if vision is affected | | Orbital MRI | T2-bright swollen extraocular muscles | Confirm CAS with ophthalmologist | | TSH (normal) | 0.5-4.5 mU/L | TED can still be present; check TRAb, TSI |

A woman can have full-blown TED with a completely normal TSH. This is called euthyroid TED and occurs because the orbit responds to TRAb independently of how the thyroid gland responds. This point is frequently missed in primary care, delaying diagnosis by months. If you have classic eye signs and a normal TSH, ask specifically for TRAb and TSI, not just a repeat TSH.

Treatment Options: From Lifestyle to Biologics

TED treatment is stratified by severity (mild, moderate-to-severe, sight-threatening) and by disease activity (active vs. Inactive/fibrotic phase). Treating during the active phase produces the best outcomes.

Mild TED: Start Here

• Smoking cessation: The single most important modifiable intervention. Smoking doubles the risk of TED progression and cuts the response to immunosuppressive treatment in half. A Cochrane-level review found smoking cessation significantly reduces TED severity and slows disease course.
• Selenium 200 mcg/day for 6 months: The EUGOGO selenium trial (a randomized controlled trial, NEJM 2011) showed selenium supplementation versus placebo improved mild TED outcomes and quality of life at 6 months. This effect was seen in selenium-replete European populations; whether it translates to selenium-sufficient North American women is less clear.
• Preservative-free artificial tears: Used throughout the day to protect the cornea from exposure.
• Moisture chamber goggles at night: For women with incomplete eyelid closure.
• Prism glasses: For mild stable diplopia.

Moderate-to-Severe Active TED: Anti-Inflammatory Therapy

IV methylprednisolone (glucocorticoids): The traditional backbone of moderate-to-severe TED treatment. Typical protocols use 12 weekly infusions totaling 4.5 g. Oral steroids are less effective and carry a higher side-effect burden for the same efficacy.

Teprotumumab (Tepezza): An IGF-1 receptor inhibitor approved by the FDA in January 2020 for active TED. In the OPTIC trial (a phase 3 RCT published in Ophthalmology 2021), teprotumumab reduced proptosis by 2 mm or more in 83% of patients versus 10% on placebo, a difference that is clinically dramatic.

Women of reproductive age receiving teprotumumab must use effective contraception during treatment and for at least 6 months after the final infusion. The drug is contraindicated in pregnancy. Hearing changes (tinnitus, hearing loss) have been reported in up to 25% of recipients and warrant baseline and periodic audiology assessments.

Mycophenolate mofetil: Used as a steroid-sparing agent or in combination with glucocorticoids. Mycophenolate is a known teratogen classified FDA category D (substantial human evidence of fetal harm). Women using mycophenolate must use two forms of reliable contraception and have a negative pregnancy test before starting.

Sight-Threatening TED: Urgent Management

Compressive optic neuropathy requires same-day high-dose IV glucocorticoids and urgent orbital decompression surgery if no response occurs within 2 weeks. This is an ophthalmologic emergency. Do not wait for an endocrinology appointment if your vision is changing.

Thyroid-Directed Treatment and TED: An Important Nuance

How you treat Graves hyperthyroidism matters for your eyes. Radioactive iodine (RAI) therapy can worsen TED, particularly in smokers and in those with moderate-to-severe baseline eye disease. ACOG and the American Thyroid Association note that RAI should be preceded by prophylactic glucocorticoids in patients with active TED. Antithyroid drugs (methimazole) and thyroidectomy carry a lower risk of worsening TED compared to RAI.

Pregnancy, Postpartum, and Lactation: What You Need to Know

If you have TED and you are pregnant, planning pregnancy, or recently postpartum, this section is essential reading.

During pregnancy: TED often improves during the second and third trimesters because pregnancy shifts immunity toward Th2 tolerance. However, TRAb levels must be checked at diagnosis and again at 18-22 weeks and 30-34 weeks in women with active Graves disease. ACOG Practice Bulletin No. 223 on thyroid disease in pregnancy specifies that TRAb levels three times or more above the upper limit of normal in the third trimester predict neonatal thyroid dysfunction. The fetus has TSH receptors in the orbits too, though fetal TED is rare.

Methimazole in pregnancy: Methimazole is teratogenic in the first trimester (associated with aplasia cutis and choanal atresia). Propylthiouracil (PTU) is preferred in the first trimester, with transition back to methimazole in the second trimester due to PTU's hepatotoxicity risk. Both drugs cross the placenta.

Teprotumumab in pregnancy: Contraindicated. Animal data show fetal harm at clinically relevant doses. Women must use reliable contraception throughout the infusion course and for 6 months afterward.

Breastfeeding: Methimazole at doses up to 20-30 mg/day is considered compatible with breastfeeding per the American Thyroid Association 2017 guidelines, though doses should be taken after nursing. IV steroids used for TED flares are generally considered compatible with breastfeeding, with a 4-hour pause after infusion sometimes recommended to minimize infant exposure. Teprotumumab has no human lactation data; breastfeeding is not recommended during treatment.

Postpartum surveillance: Women with a known history of Graves disease or positive TRAb should be monitored clinically for TED flare in the 6-12 months after delivery. Any new proptosis, worsening diplopia, or corneal symptoms in this window warrants urgent ophthalmology referral.

Who Is This Condition Right For? Who Needs the Most Urgent Attention?

Act the Same Day If You Have:

• Sudden vision blurring or loss of color vision
• Rapid eye protrusion developing over days to weeks
• Inability to close your eyelids fully (exposure risk)
• Eye pain at rest (not just with movement)

Refer to Endocrinology and Ophthalmology Within 1-2 Weeks If You Have:

• Confirmed Graves disease plus any eye symptom at all
• Positive TRAb with periorbital swelling or double vision
• Euthyroid TED (normal TSH but positive TSI/TRAb with eye signs)
• Postpartum onset of new eye changes

You Can Start With Your Primary Clinician If You Have:

• Mild gritty dryness with known Graves disease and stable labs
• Mild lid puffiness without proptosis or diplopia
• Newly detected TPO antibodies, normal thyroid function, and no eye signs (monitor; do not treat)

Conditions That Frequently Co-Occur and Complicate TED

• PCOS: Women with PCOS have a higher prevalence of thyroid autoimmunity, with TPO antibody positivity reported in up to 27% in some cohorts.
• Type 1 diabetes: Polyglandular autoimmune syndrome; TED can cluster with other autoimmune conditions.
• Celiac disease: Associated with thyroid autoimmunity; consider screening in women with difficult-to-control Graves disease.
• Female pattern hair loss: Thyroid dysfunction (both hypo and hyperthyroidism) contributes to diffuse hair shedding and is easily overlooked in a TED workup.

The Evidence Gap: What We Do Not Yet Know for Women

Women represent approximately 80% of TED patients, yet sex-stratified data in TED trials remains thin. The OPTIC trial (teprotumumab) did not publish sex-stratified outcomes. The selenium EUGOGO trial enrolled predominantly women but did not analyze hormonal-status subgroups. Perimenopausal and postmenopausal women are rarely analyzed as a distinct group in TED research despite the known immune shifts at menopause.

Practically, this means that dosing thresholds for intervention, response rates to teprotumumab, and optimal steroid protocols in women across the reproductive spectrum are extrapolated from mixed-sex or female-majority but unstratified data. This gap is worth naming when you discuss treatment options with your clinician.

As WomanRx reviewer Dr. Maya Okafor notes: "I routinely see women in perimenopause whose proptosis has been attributed to aging or stress for 12-18 months before anyone checks a TRAb. A single additional tube of blood at the initial workup changes everything."